Gossamer Bio (NASDAQ:GOSS) Sets New 12-Month High at $26.42

Share on StockTwits

Gossamer Bio Inc (NASDAQ:GOSS) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $26.42 and last traded at $26.25, with a volume of 5831 shares changing hands. The stock had previously closed at $25.21.

GOSS has been the subject of several recent analyst reports. ValuEngine cut shares of Gossamer Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Evercore ISI set a $30.00 price target on shares of Gossamer Bio and gave the company a “buy” rating in a research report on Monday, August 12th. Bank of America assumed coverage on Gossamer Bio in a research note on Tuesday. They set a “buy” rating and a $32.00 price target on the stock. Zacks Investment Research cut Gossamer Bio from a “hold” rating to a “sell” rating in a report on Tuesday, August 20th. Finally, Berenberg Bank began coverage on Gossamer Bio in a research note on Wednesday, October 30th. They issued a “buy” rating and a $31.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $28.83.

The stock has a market capitalization of $1.68 billion and a price-to-earnings ratio of -1.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 13.64 and a current ratio of 13.64. The firm has a fifty day moving average of $21.46 and a 200-day moving average of $20.10.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.10). On average, analysts predict that Gossamer Bio Inc will post -3.26 EPS for the current year.

In related news, major shareholder Faheem Hasnain acquired 28,700 shares of the firm’s stock in a transaction on Wednesday, September 25th. The shares were acquired at an average cost of $2.51 per share, with a total value of $72,037.00. Also, major shareholder Fund V. Gp L.P. Omega sold 183,607 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $21.96, for a total transaction of $4,032,009.72. Over the last 90 days, insiders have bought 40,821 shares of company stock worth $275,497 and have sold 400,000 shares worth $8,674,719. 23.30% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in GOSS. BNP Paribas Arbitrage SA acquired a new stake in shares of Gossamer Bio during the second quarter worth $42,000. Bank of Montreal Can grew its position in shares of Gossamer Bio by 144.7% in the 2nd quarter. Bank of Montreal Can now owns 2,839 shares of the company’s stock valued at $63,000 after acquiring an additional 1,679 shares during the period. JPMorgan Chase & Co. grew its position in shares of Gossamer Bio by 87.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,995 shares of the company’s stock valued at $126,000 after acquiring an additional 2,798 shares during the period. Royal Bank of Canada increased its stake in shares of Gossamer Bio by 39.3% during the 2nd quarter. Royal Bank of Canada now owns 6,967 shares of the company’s stock worth $154,000 after purchasing an additional 1,967 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new stake in shares of Gossamer Bio in the 3rd quarter valued at about $239,000. 61.47% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Read More: What are Bollinger Bands?

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.